Theravance Biopharma Presents Positive New Data

Theravance Biopharma said on Monday multiple studies of its antibiotic drug Vibativ against difficult-to-treat Staphylococcus aureus pathogens, including those considered to be multi-drug resistant, as compared to other commercialized antibiotics, showed positive new data.

Theravance, presenting the studies at the 2017 annual meeting of the American Society for Microbiology (ASM), said the findings demonstrated greater in vitro activity for Vibativ as compared to other well-known antibiotics such as vancomycin, daptomycin, ceftaroline and linezolid.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Comment